On October 27, 2026, San Francisco-based Vera Health announced a $28.5 million Series A led by Threshold Ventures, with participation from Optum Ventures, Mantis VC, and SV Angel. Existing investors Y Combinator and Gradient increased their backing in the round, bringing the company's total funding to $32 million.
Vera Health is a clinical AI search engine — a tool that helps physicians find and evaluate medical evidence in seconds. Its growth story is striking: a year ago, only a few thousand clinicians were using it. Today, more than 800,000 clinicians across 190 countries use it, most having discovered it through a colleague. Every month since June 2026, Vera has been the most downloaded clinical app in the world across the App Store and Google Play, according to download data cited by the company.
How Vera differs from a general-purpose chatbot
The core idea behind Vera is simple but consequential: in medicine, not all evidence is equal, and an AI tool should not pretend otherwise. A large randomised trial and a single-patient case report should never carry the same weight, yet most AI tools blend them into the same confident answer.
Vera reverses the usual order. It searches first, then writes. The platform searches more than 60 million scientific publications, clinical guidelines, consensus statements, and drug labels, evaluates the evidence, and only then generates an answer. Every claim is linked to its supporting research and colour-coded to show the strength of the available evidence.
Sometimes that colour is red. A rare condition may have only a small case series or a single-patient report behind it. Vera surfaces that research while making its limitations visible, so physicians can judge how much weight the findings deserve. As co-founder Maxime Allouch put it, "Unlike other tools, we believe there's value in making uncertainty visible. The grade shapes what Vera retrieves and writes, while the clinician brings the patient, the context and the judgment."
The approach has won institutional support. Through a partnership with the American College of Emergency Physicians, Vera integrates the college's clinical policies with source attribution. Scott M. Silvers, chair of the college's Clinical Policies Committee, said that level of evidence "is the foundation of every guideline we write, and Vera Health is built on it."
A small team, a global footprint
Vera's growth has been achieved with a team of just 12 employees — doubling from six to 12 while reaching more than 800,000 clinicians. The company says roughly 1 in 4 physicians in Spain and Italy use it, and about 1 in 7 in France, largely through word of mouth. In September 2026 alone, it was downloaded more times than OpenEvidence and Doximity combined, according to the company, while monthly downloads had more than tripled since February.
What the funding will support
The financing will support further development of Vera's clinical evidence infrastructure, expansion into additional healthcare markets, and deeper partnerships with medical societies, publishers, and health systems. The company is hiring internationally, close to the clinicians and health systems it serves, as it grows faster in local markets.
Why it matters for founders and investors
For founders, Vera is a lesson in distribution through trust. It did not buy its way to 800,000 users with advertising; it earned them through a product that clinicians could check, challenge, and recommend to colleagues. In high-stakes professional markets — medicine, law, finance — the ability to show your work is not a nice-to-have feature. It is the distribution strategy.
For investors, clinical AI is one of the most promising but most scrutinised areas of applied AI. The regulatory, liability, and accuracy bar is far higher than for general consumer tools, and a single high-profile error can destroy trust. Vera's evidence-grading approach is an attempt to design for that scrutiny from the start, rather than bolting it on later. The diligence question is whether that rigour survives scale: as Vera expands across specialties, countries, and health systems, can it keep answers accurate, local, and honest about uncertainty — while converting a large free user base into sustainable institutional revenue?
The company's own anecdote points to what is at stake. Chief Scientific Advisor Dr. Bernard P. Chang described an emergency-department shift in which Vera surfaced evidence that raised concern for a pulmonary embolism — a potentially life-threatening blood clot — in a patient whose symptoms could easily have been attributed to a routine respiratory illness, leading him to broaden his evaluation. That is the promise of clinical AI at its best: not replacing judgment, but challenging assumptions at the moment it matters.
Angeled.com connects founders with investors.
Source: https://www.verahealth.ai/blog/vera-health-raises-32-million
Read Next
General Translation Raises $27 Million Series A Led by a16z to Build Agent-First Localization Infrastructure
LangChain Raises $300 Million Led by CapitalG at a $3 Billion Valuation to Build the Agent Stack
Mount Thor Raises $45 Million to Run Cloud Fleets of Macs for AI Agents
OpenAI Reportedly Raises $15 Billion at a $1.25 Trillion Valuation
Q-CTRL Raises $290 Million Series C Led by Salesforce Ventures, Reaching Unicorn Status
SE3 Raises $30 Million Series A Led by Accel



